dr. hammers on nivolumab/ipilimumab data in rcc
Published 7 years ago • 356 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:51
dr. hammers on study of hyperacute renal immunotherapy in rcc
-
1:17
dr. hammers on the checkmate-214 study for rcc
-
1:20
dr. hammers on immunotherapy combinations in kidney cancer
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc
-
1:21
dr. hammers on the long-term benefits of the checkmate-214 study in rcc
-
3:09
dr hans hammers discusses the clinical trial of nivolumab plus ipilimumab in renal cell carcinoma
-
1:17
dr. hammers on the future of immunotherapy in rcc
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
0:56
dr. hammers on next steps with immunotherapy in rcc
-
1:18
dr. hammers on challenges with car t-cell therapy in rcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
1:34
fda approval of frontline nivolumab/ipilimumab combo in rcc
-
1:37
dr. hammers on combinations of ido and pd-1 inhibitors in rcc
-
1:42
dr. hammers on combination strategies in kidney cancer
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
1:58
dr. plimack on significance of checkmate-025 trial in rcc
-
4:05
long-term rcc data with nivolumab
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab